Crizotinib-d9
Crizotinib-d9 (PF-02341066-d9) is deuterium labeled Crizotinib. Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition[1][2][3].
Product Specifications
CAS Number
[1523580-59-7]
Product Name Alternative
PF-02341066-d9
UNSPSC
12352005
Target
Isotope-Labeled Compounds
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
C[C@H](C1=C(C(F)=CC=C1Cl)Cl)OC2=CC(C3=CN(C4([2H])C([2H])([2H])C([2H])([2H])NC([2H])([2H])C4([2H])[2H])N=C3)=CN=C2N
Molecular Formula
C21H13D9Cl2FN5O
Molecular Weight
459.39
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Lentiviral mouse Atoh8 shRNA (UAS) - Lentiviral mouse Atoh8 shRNA (UAS, GFP) (100)
